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Abstract
Persistent gag-specific Tcell immunity would be a useful component of an effective HIV vaccine. The Flavivirus Kunjin replicon was previously
engineered to persistently express HIV gag and was shown to induce protective responses in mice. We evaluated Kunjin replicon virus-like-particles
expressing SIVgag–pol in pigtail macaques. Kunjin-specific antibodies were induced, but no SIV-specific Tcell immunity were detected. Following
SIVmac251 challenge, there was no difference in SIV viremia or retention of CD4 T cells between Kunjin–SIVgag–pol vaccine immunized animals
and controls. An amnestic SIV gag-specific CD8 T cell response associated with control of viremia was observed in 1 of 6 immunized animals.
Refinements of this vector system and optimization of the immunization doses, routes, and schedules are required prior to clinical trials.
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HIV infections remain a major threat to global health. A
prophylactic vaccine is urgently required, but attempts to induce
broadly reactive neutralizing antibodies or protective T cell im-
munity have thus far failed (2007; Cohen, 2003). Most studies
have shown that following HIV-1 infection of humans and SIV
infection of macaques, CD8 and CD4 T cell responses correlate
with control of acute infection, lowered viremia and in some
situations improved survival (Johnston and Fauci, 2007;⁎ Corresponding author.
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doi:10.1016/j.virol.2008.01.006Schmitz et al., 1999). Several studies have shown that T cell
immunity to SIVor chimeric SHIV induced by vaccination does
not prevent infection but results in reduced levels of viremia and
prevention of immunodeficiency in macaques (Amara et al.,
2001; Barouch et al., 2000; Dale et al., 2004; Wilson et al.,
2006).
There has been recent interest in several qualitative aspects of
HIVor SIV-specific CD4 and CD8 Tcell immunity. Gag-specific
T cell immunity may be more beneficial than T cell responses to
other antigens (Kiepiela et al., 2007; Sacha et al., 2007).
Expression of multiple effector cytokines, chemokines and
degranulation molecules from HIV-specific T cells has also
been shown to be beneficial (Betts et al., 2006). Generation of
long-lived T cells with the appropriate effector and memory
phenotypesmay be required for durable immunity (Almeida et al.,
2007; Fernandez et al., 2007; Sun et al., 2005).
529S.J. Kent et al. / Virology 374 (2008) 528–534Many viral and bacterial vectors have been utilized to express
HIV or SIV antigens from within cells and thereby prime T cell
immunity. Replication-incompetent adenovirus- and canarypox-
HIV vaccine vectors have entered advanced clinical trials
(Johnston and Fauci, 2007). Most recombinant vector-based
vaccine studies have not shown as efficient in control of virulent
SIV challenge as live attenuated SIV vaccines for reasons that
remain unclear (Koff et al., 2006). We recently showed that
recombinant poxvirus vector-based vaccines, which typicallyFig. 1. Tcell immunogenicity of Kunjin–SIV/HIV vaccines. 12 animals were vaccinated
gag vaccines (closed symbols). Antigen-specific IFNγ expression from CD4+3+ or CD8
All animals were challengedwith SIVmac251 at week 24 (large arrow) A. SIV gag-specific
macaques have solid symbols and Kunjin–HIV-vaccinated macaques have open symb
responses by vaccine group. E. CD8 Tcells to the SIV gag epitope KP9 were tracked in 2express the inserted SIV genes only transiently, induce SIV-
specific CTLs with slow kinetics of killing in comparison to live
attenuated vaccines (Rollman et al., 2007). There has been recent
interest in replication-competent virus vectors that can persis-
tently express the inserted HIV/SIV antigens (Evans et al., 2005;
Kaur et al., 2007). Persistent vectors however face tough
regulatory hurdles for clinical trials. Safer vectors incapable of
in vivo packaging and spread that express high levels of persisting
antigen are needed.(small arrows) with Kunjin–SIV gag/RT vaccines (open symbols) or Kunjin–HIV
+3+ T lymphocytes was assessed on fresh blood by intracellular cytokine staining.
CD4 andB. CD8Tcell responses from individual animals. Kunjin–SIV-vaccinated
ols. C. Mean SIV gag-, SIV RT- and HIV-1 gag-specific CD4 and D. CD8 T cell
Mane-A⁎10+ animals (one in each vaccine group) by a Mane-A⁎10/KP9 tetramer.
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vaccines since they can be engineered to express high levels of
antigens. Venezuelan Equine Encephalitis, Sindbis and other
alphavirus replicon vectors have shown induction of some T cell
immunity in macaques (Davis et al., 2000; Gupta et al., 2006; Xu
et al., 2006). A potential disadvantage of alphavirus replicon
vectors is the transient antigen expression following apoptosis of
infected antigen-expressing cells and high frequency of recombi-
nation during VLP preparations giving rise to infectious recom-
binant viruses. Replicons of an Australian Flavivirus Kunjin has a
diminished capacity to induce apoptosis in infected cells, thereby
allowing prolonged antigen expression and induction of high
levels of Tcell immunity (Anraku et al., 2002; Harvey et al., 2003;
Herd et al., 2004). Kunjin–HIVgag vaccine vectors have induced
high levels of long-lived CD8 T cell immunity in mice (Harvey
et al., 2003). The promise of the current-generation of Kunjin
replicon–HIV vaccine vectors thus warranted evaluation in
primates.
Results and discussion
We randomized twelve pigtail macaques 1:1 to receive either
Kunjin VLPs expressing either SIV gag/RT or HIV gag (controlFig. 2. Humoral immunity of Kunjin–SIV vaccine. Western Blots (WB) for antibodies t
2 weeks after the 3rd vaccination (lane 1, week 10), 2 weeks after the 4th vaccination (la
challenge (lane 4, week 26), 7 weeks after challenge (lane 5, week 31) and 16weeks afte
are shown onKunjin/HIV-vaccinated (A) andKunjin/SIV-vaccinated (B)macaques. Siz
together with a serial 2-fold dilution (dil) of the positive sera and shown at the right ofgroup) 4 times at 0, 4, 8 and 18 weeks (see arrows, Fig. 1A). The
vaccinations were safe, not inducing marked injection site re-
actions or changes in hematology profiles (not shown).
Following the initial and the 3 booster vaccinations, no sig-
nificant HIVor SIV-specific CD4 or CD8 T cell responses were
detected by IFNγ intracellular cytokine analyses on fresh whole
blood (Fig. 1). In addition, no responses were found by staining
for the cytokines TNFα or IL-2 (not shown). No SIV gag KP9-
specific responses were detected in the 2 Mane-A⁎10+ animals
by KP9/Mane-A⁎10 tetramer staining prior to SIV challenge
(Fig. 1E).
To study humoral immunity following vaccination with KUN-
SIVgag/pol vaccine, we examined SIV-specific antibodies fol-
lowing the vaccinations by Western Blot as previously described
(Batten et al., 2006) (Fig. 2). No SIV gag-specific antibodies
appeared to be induced by vaccination— some non-specific p24/
p26 gag bands were present at baseline that did not expand after
vaccination. Two weeks following the 3rd and 4th vaccinations
(week 10 and 20, lanes 1, 2 in Fig. 2), bands were present to the
p66/68 region in both Kunjin–SIV and Kunjin–HIV vaccinated
macaques. These bands were not expanded after SIV challenge
(lanes 4–6, Fig. 2). Similar bands were detected after vaccination
in Kunjin–HIV vaccinated using a HIV-1 Western Blot (noto SIVantigens were performed from plasma from pre-vaccination (lane 0, week 0),
ne 2, week 20), on the day of SIVmac251 challenge (lane 3, week 24), 2 weeks after
r challenge (lane 6, week 40). HIV-2Western Blots to detect SIV-specific antibodies
e standard are shown at the left and positive (+) and negative (−) control human sera,
panel A.
531S.J. Kent et al. / Virology 374 (2008) 528–534shown). The Kunjin–HIV vaccine does not express Pol antigens
suggesting the bands were not specific to Pol antigens and may
represent cross-reactive responses to Kunjin virus antigens.
Although no T and B cell immune response to SIV antigen
were detected after the Kunjin VLP vaccinations, it was possible
that some low-level responses were primed. To address this pos-
sibility the macaques were tested for vector-specific immune
responses using an overlapping 18 mer peptide library covering
the Kunjin virus NS3 protein. NS3 is expressed intracellularly by
the replicon and known to be a target of Flavivirus-specific T cell
immunity inmice and in humans (Appanna et al., 2007; Hill et al.,
1992; Kumar et al., 2004; Simmons et al., 2005). Kunjin NS3-
specific T cell immunity was examined by ICS at multiple time
points during the course of vaccination. No significant CD4 or
CD8 T cell immune responses were detected to Kunjin NS3
peptides in any of the 12 Kunjin–HIV and Kunjin–SIV
immunized animals (b0.1% of CD4 or CD8 T cells expressing
IFNγ). To assess humoral immunity elicited to the inoculated
VLPs, we studied neutralizing antibodies to Kunjin virus directed
against envelope protein present as structural component of VLPs
but not expressed by the replicon (Hall et al., 2003). As expected,
Kunjin-specific neutralizing antibodies were detected after
vaccination in all 12 animals after 3 vaccinations, with no overall
differences between the 2 vaccine groups (Fig. 3). There wereFig. 3. Kunjin virus specific neutralizing antibodies. Neutralizing antibodies were
followed after the 3rd vaccination. A. All animals are shown — Kunjin–SIV-
vaccinated macaques have open symbols and Kunjin–HIV-vaccinated macaques
have closed symbols. B. Mean (±SE) of both vaccine groups is shown.modestly higher Kunjin-specific antibodies detected in the
Kunjin–HIV vaccines after 1 vaccination (week 4, Fig. 3B),
potentially reflecting the higher dose of VLPs used in the Kunjin–
HIV vaccinations. After 3 vaccinations the Kunjin antibody
responses were similar between the 2 vaccine groups suggesting
an adequate dose of VLP vaccination was used for both vaccine
groups.
At week 24 after the initial vaccination, all 12 animals were
challenged intravenously with a pathogenic stock of SIVmac251
(Batten et al., 2006). All macaques became infected, with mean
peak viral loads 2 weeks after inoculation in all 12 animals of 7.0
(range 6.1 – 8.1) log10 copies of SIV RNA/ml plasma. There was
no significant difference in mean viral loads between Kunjin–
SIV-vaccinated animals and Kunjin–HIV-vaccinated animals out
to 23 weeks after infection (Fig. 4A). Mean peak and set point
(between weeks 5–23 after infection) viral loads between vac-
cinated and control animals were almost identical (7.1 vs. 6.9 and
5.6 vs. 5.5 log10 copies/ml respectively). Only one macaque (the
Mane-A⁎10+ animal in theKunjin–SIV vaccinated group, animal
5612) subsequently controlled its viral load (Fig. 4B). A gradual
decline in peripheral CD4 T cells was observed in both groups,
without significant differences between the groups (Figs. 4C, D).
Four of the 12 macaques (2 in each vaccine group) were
euthanised prior to 23 weeks of follow-up. All 4 euthanised
macaques had high viral loads (N6.0 log10 copies/ml), CD4 Tcell
depletion (b20%), failure to gain weight and thrombocytopenia
(b100/μl), consistent with incipient AIDS.
To further address whether SIV-specific immune responses
were primed by vaccination, we analyzed whether a sharp
anamnestic T cell and antibody response was observed early after
challenge. No overall differences in SIV-specific CD4 or CD8 T
cell responses after challenge were observed between the 2
vaccine groups (Figs. 1A–D).No rapid recall response of SIV gag
antibodies was observed in the SIV vaccine group (Fig. 2). One
Kunjin–SIV vaccinated Mane-A⁎10+ macaque (animal 5612)
did however have a large (N10%) SIV gag KP9 epitope-specific
response detected early (within 2weeks) after challenge (Fig. 1E).
The KP9 response was likely primed by vaccination since (a) the
control Mane-A⁎10+ animal that received the Kunjin–HIV
vaccine had no early rise in KP9-specific CD8 T cells and
(b) our previous experience with 24 Mane-A⁎10+ macaques
demonstrated a slow pattern of generating KP9-specific CD8 T
cells in the absence of prior vaccination (Fernandez et al., 2007).
One Kunjin–HIV vaccinated animal (#5807) generated a 1.0%
SIV gag-specific CD8 Tcell response early after challenge (black
diamonds, Fig. 1B), but this was not sustained and likely reflects a
de novo response to SIV infection.
In summary, althoughKunjin repliconVLPvaccines expressed
HIVand SIVgag efficiently in vitro and are immunogenic inmice,
this was a largely negative macaque study. With the exception of
theMane-A⁎10+ animal (see below), no induction of SIV-specific
immunitywas detected in pigtail macaques and no protection from
a pathogenic SIVmac251 challenge was observed. No Kunjin
vector-specific T cell responses were detected prior to challenge,
although neutralizing antibodies to the structural component of the
Kunjin replicon delivery vehicle (VLPs) were readily detected in
all animals. This is consistent with extracellular recognition of the
Fig. 4. Outcomeof SIVmac251 challenge. Plasma viremia and peripheral CD4Tcell levels followed after challenge for 23weeks. A,C.All animals are shown—Kunjin–SIV
vaccinated macaques have open symbols and Kunjin–HIV vaccinated macaques have closed symbols. B, D. Mean (±SE) of both vaccine groups is shown. 4 animals (2 in
each group) were euthanised prior to the completion of the study and the last-observation is carried forward for the mean of the groups for the last 2 time points.
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Kunjin or SIV genes. Apparent blockade of entry or replication of
the Kunjin replicons in primates under immunization conditions
used in this study was not expected and is currently under further
evaluation. Mouse experiments suggest that efficient vaccination
is achieved with intraperitoneal administration, which may have
elicited better responses in macaques compared to the intramus-
cular or subcutaneous administrations used in this study. Antigen-
presenting cells of specific types or local concentrations of anti-
viral responses at the sites of injectionmay be important mediators
of vaccine efficacy of this (and perhaps other) replicon system.
No early anamnestic T cell or antibody responses to the
SIVmac251 challenge were observed in 5 of the 6 Kunjin–SIV
vaccinated animals. However, the oneMane-A⁎10+ Kunjin–SIV
vaccinated animal (#5612) had a rapid rise in SIV gag-specific
CD8 T cells early after challenge, detected by both ICS (5.5% of
CD8 T cells expressing IFNγ to gag) and Mane-A⁎10/KP9
tetramer (11% of CD8 T cells). This is consistent with priming of
SIV gag KP9-specific CD8 T cells by vaccination, although we
did not detect priming with our whole blood ICS or tetramer
assays.We also performed a cultured IFNγ ELISpot in an attempt
to detect low-level primed responses by adapting a published
human assay (Goonetilleke et al., 2006). Again we did not detect
any SIV-specific responses in the 12 animals, although the assaycould require further optimization and validation for macaque
cells (not shown). Nonetheless, Kunjin–SIV vaccinated animal
5612 subsequently controlled SIVmac251 viremia within 10 weeks
following challenge and did not experience a CD4 T cell decline.
Although this single animal suggests that effective priming of
SIV-specific immunity may be possible with Kunjin–SIV vac-
cines, improvements and further optimization of vector prepara-
tions, immunization doses, routes and schedules are clearly
needed to more broadly and robustly induce immunity to SIV
antigens in primates with this technology.
Materials and methods
Vaccines
Kunjin virus replicon vaccines, KUN–SIVgag–pol, expres-
sing SIVmac239 gag matrix and nucleocapsid connected in frame
with reverse transcriptase (RT) and KUN–HIV gag expressing
HIV-1 gag were constructed as described elsewhere ((Harvey
et al., 2003), Anraku et al. submitted). The Kunjin replicon
vaccines were produced in the form of virus-like particles (VLPs)
by transfecting KUN–SIVgag–pol replicon RNA into tet-
KUNCprME packaging cells as described previously (Harvey
et al., 2004). The VLPs were concentrated by tangential flow
533S.J. Kent et al. / Virology 374 (2008) 528–534filtration (300 kDa cut off) and then spinning the preparation
through a sucrose cushion (12.5% sucrose and 2.5% trehalose).
The pellets were resuspended in DMEM and frozen at−70 °C in
aliquots. Antigen expression from both vaccines in vitro was
confirmed as previously described ((Harvey et al., 2003), Anraku
et al. submitted).
Macaques
Twelve juvenile pigtail macaques (Macaca nemestrina) were
studied in a protocol approved by the University of Melbourne
and CSIRO Livestock Industries animal ethics committees.
Macaques were stratified by weight, gender and the MHC class I
allele Mane-A⁎10 (1 animal each group, 5612 in the Kunjin–
SIV group and 3C7D in the Kunjin–HIV group) identified as
previously described (Smith et al., 2005b). Mane-A⁎10 presents
the immunodominant KP9 SIV gag epitope and results in
delayed progression to AIDS (Smith et al., 2005a). Immuniza-
tions were given in equal doses (1.2×108 VLPs for Kunjin–SIV
and 8×108 VLPs for Kunjin–HIV in 1 ml) by the intramuscular
and subcutaneous routes over the thigh in opposite legs.
Immunogenicity testing
SIV- and HIV-specific T cell responses were assessed by
intracellular cytokine staining for IFNγ expression. Fresh whole
blood (200 μl) was stimulated for 6 h with overlapping 15 mer
peptide sets spanning SIVmac239 gag, SIVmac239 RT, or HIV-1
consensus subtype B gag (all from NIH AIDS Reagent
repository) as described (De Rose et al., 2007).We also examined
fresh blood for SIV gagKP9-specific CD8Tcells by stainingwith
the Mane-A⁎10/KP9 MHC tetramer in the 2 Mane-A⁎10+
animals as previously described (Fernandez et al., 2007). SIV-
specific antibodies were assessed in macaque sera samples by
Western Blot to a HIV-2 antigen preparation as described (Batten
et al., 2006). Macaque blood was also tested for vector-specific
immune responses by intracellular cytokine staining for IFNγ
expression using an overlapping 18 mer peptide library covering
the Kunjin virus NS3 protein (88 18 mer peptides overlapping by
11) (GL Biochem, Shanghai, China). Serum neutralizing anti-
bodies to Kunjin virus directed against envelope protein present
as structural component of VLPs were assessed as previously
described (Hall et al., 2003).
Virus challenge
At week 24 after the initial vaccination, all 12 animals were
challenged intravenouslywith a pathogenic stock of SIVmac251 (40
TCID50) we have used previously in pigtail macaques (Batten
et al., 2006). We monitored SIV RNA in plasma and peripheral
CD4 T cell depletion as previously described (De Rose et al.,
2007).
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